Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02648932 · ClinicalTrials.gov registry record · Phase 2

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

A Phase 2 study, sponsored by University of Chicago.

Terminated
Registry status
Phase 2
Development phase
9
Enrollment target

NCT02648932 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02648932, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.

TERMINATED
Registry status
Phase 2
Development phase
9 participants
Enrollment target

Study Summary

The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

Interventions

  • BIOLOGICAL Haplo-Cord Transplant
  • PROCEDURE Matched Unrelated Donor Transplant

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2016-02-04
Est. Completion 2020-04
Phase Phase 2

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT02648932

The ClinicalTrials.gov registry entry for NCT02648932 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Haplo-Cord Transplant is the first listed.

NCT02648932 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02648932 about?

NCT02648932 is a clinical study titled "The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients". The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

What is the current status of trial NCT02648932?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-02-04. Estimated completion is 2020-04.

What interventions are being tested in trial NCT02648932?

The interventions under investigation include: Haplo-Cord Transplant (BIOLOGICAL), Matched Unrelated Donor Transplant (PROCEDURE).

Who is sponsoring clinical trial NCT02648932?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.